378 related articles for article (PubMed ID: 23146291)
1. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
[TBL] [Abstract][Full Text] [Related]
2. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy.
Terzis G; Dimopoulos F; Papadimas GK; Papadopoulos C; Spengos K; Fatouros I; Kavouras SA; Manta P
Mol Genet Metab; 2011 Nov; 104(3):279-83. PubMed ID: 21640624
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
4. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
[TBL] [Abstract][Full Text] [Related]
6. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
[TBL] [Abstract][Full Text] [Related]
7. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
Case LE; Beckemeyer AA; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
[TBL] [Abstract][Full Text] [Related]
8. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
9. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
[TBL] [Abstract][Full Text] [Related]
10. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
11. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
12. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
Lacaná E; Yao LP; Pariser AR; Rosenberg AS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
[TBL] [Abstract][Full Text] [Related]
13. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
[TBL] [Abstract][Full Text] [Related]
15. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
Kishnani PS; Beckemeyer AA; Mendelsohn NJ
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
[TBL] [Abstract][Full Text] [Related]
16. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
Bernstein DL; Bialer MG; Mehta L; Desnick RJ
Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
[TBL] [Abstract][Full Text] [Related]
17. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
19. New insights into therapeutic options for Pompe disease.
Richard E; Douillard-Guilloux G; Caillaud C
IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
[TBL] [Abstract][Full Text] [Related]
20. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
Andreassen CS; Schlütter JM; Vissing J; Andersen H
Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
